LaToya Edwards

LaToya Edwards

Senior Associate

LaToya Edwards advises domestic and international companies in a wide range of corporate transactions, including mergers and acquisitions, divestitures, strategic alliances, corporate reorganizations, commercial transactions and licensing and collaboration arrangements. She has broad experience representing clients in a variety of industries, including life sciences, private equity, technology and consumer products.

Ms. Edwards has spent significant time as in-house counsel for key pharmaceutical clients of the firm, working alongside legal and business teams as a secondee attorney. At Novartis, Ms. Edwards played an integral role in the commercial launch of KYMRIAH, a pioneering CAR-T cell therapy drug. At Sanofi, she served as legal point of contact for a newly acquired subsidiary, advising on all matters relating to manufacturing and supply agreements, transition concerns, and the general legal needs of the industrial affairs group. As a result of her experience, Ms. Edwards offers a real-world understanding of the in-house corporate legal function and the need to work efficiently with corporate executives on legal and commercial issues.

Ms. Edwards attended Duke University School of Law, where she served as an officer of the Moot Court Board, Articles Editor of the Duke Journal of Gender Law and Policy and was named a Mordecai Scholar. She is a 2006 inductee into the University of Florida Hall of Fame for excellence in leadership.

Prior to entering private practice, Ms. Edwards served as a federal law clerk to the Honorable Morrison C. England, Jr., US District Court for the Eastern District of California.

Experience

  • AstraZeneca in its agreement with the government of the United Kingdom for the manufacturing and supply of the University of Oxford's potential COVID-19 vaccine.
  • Novartis in the sale to Mylan of its global cystic fibrosis products, including the TOBI® Podhaler and TOBI® solution.
  • Novartis, as a secondee, in its commercial launch of KYMRIAH, a pioneering CAR-T cell therapy drug.
  • Sanofi, as a secondee, in serving as legal point of contact for a newly acquired subsidiary's manufacturing and transition matters and in supporting the industrial affairs group.
  • Global biopharmaceutical company in drafting and negotiating clinical trial agreements and related confidentiality agreements around the world.
  • Global biotechnology company in drafting and negotiating global clinical research agreements.
  • Global pharmaceutical company in negotiating a license and collaboration agreement with a key biotechnology company.
  • Global pharmaceutical company regarding a collaboration, option and license agreement involving certain immunotherapies.

Credentials

Education
  • JD, Duke University School of Law, 2009, Mordecai Scholar
  • BA, BS, University of Florida, 2006, cum laude
Admissions
  • New York
Clerkships
  • US District Court, Eastern District of California, Morrison C. England, Jr.
Activities
  • Mentor, Justice Resource Center of New York Moot Court/Mock Trial Program
  • Mentor, America Needs You, New York Chapter
Overview

Email Disclaimer